The Cytotoxic T-Lymphocyte Associated Protein-4 (CTLA4) and programmed cell death-1 (PD-1) checkpoint pathways are inhibitory pathways, and blocking these inhibitory pathways with mAbs has triggered antitumor immune responses that altered the cancer therapy field. The gene discussed is CTLA4; the disease is cancer.